Alivus Life Sciences Ltd reported a 12% revenue increase for Q3FY25, reaching Rs. 6,418 Mn, and an EBITDA margin expansion to 31.3%. The company achieved 15.2% YoY growth in EBITDA to Rs. 2,008 Mn and generated free cash flow of Rs. 1,838 Mn.
AI Assistant
Glenmark Life Sciences Ltd
2025
Announcement
Find Answers
Ask about any part of the document to get insights, explanations, or key details.